Literature DB >> 18300945

Quantitative trait locus and computational mapping identifies Kcnj9 (GIRK3) as a candidate gene affecting analgesia from multiple drug classes.

Shad B Smith1, Cheryl L Marker, Cydne Perry, Guochun Liao, Susana G Sotocinal, Jean-Sebastien Austin, Kara Melmed, J David Clark, Gary Peltz, Kevin Wickman, Jeffrey S Mogil.   

Abstract

AIMS: Interindividual differences in analgesic drug response complicate the clinical management of pain. We aimed to identify genetic factors responsible for variable sensitivity to analgesic drugs of disparate neurochemical classes. METHODS AND
RESULTS: Quantitative trait locus mapping in 872 (C57BL/6x129P3)F2 mice was used to identify genetic factors contributing to variability in the analgesic effect of opioid (morphine), alpha2-adrenergic (clonidine), and cannabinoid (WIN55,212-2) drugs against thermal nociception. A region on distal chromosome 1 showing significant linkage to analgesia from all three drugs was identified. Computational (in silico) genetic analysis of analgesic responses measured in a panel of inbred strains identified a haplotype block within this region containing the Kcnj9 and Kcnj10 genes, encoding the Kir3.3 (GIRK3) and Kir4.1 inwardly rectifying potassium channel subunits. The genes are differentially expressed in the midbrain periaqueductal gray of 129P3 versus C57BL/6 mice, owing to cis-acting genetic elements. The potential role of Kcnj9 was confirmed by the demonstration that knockout mice have attenuated analgesic responses.
CONCLUSION: A single locus is partially responsible for the genetic mediation of pain inhibition, and genetic variation associated with the potassium channel gene, Kcnj9, is a prime candidate for explaining the variable response to these analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300945     DOI: 10.1097/FPC.0b013e3282f55ab2

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  28 in total

Review 1.  Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction.

Authors:  Jody Mayfield; Yuri A Blednov; R Adron Harris
Journal:  Int Rev Neurobiol       Date:  2015-06-22       Impact factor: 3.230

2.  The genetics of pain and analgesia in laboratory animals.

Authors:  William R Lariviere; Jeffrey S Mogil
Journal:  Methods Mol Biol       Date:  2010

3.  ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice.

Authors:  Kristian Kaufmann; Ian Romaine; Emily Days; Conrado Pascual; Adam Malik; Liya Yang; Bende Zou; Yu Du; Greg Sliwoski; Ryan D Morrison; Jerod Denton; Colleen M Niswender; J Scott Daniels; Gary A Sulikowski; Xinmin Simon Xie; Craig W Lindsley; C David Weaver
Journal:  ACS Chem Neurosci       Date:  2013-06-13       Impact factor: 4.418

4.  GIRK3 gates activation of the mesolimbic dopaminergic pathway by ethanol.

Authors:  Melissa A Herman; Harpreet Sidhu; David G Stouffer; Max Kreifeldt; David Le; Chelsea Cates-Gatto; Michaelanne B Munoz; Amanda J Roberts; Loren H Parsons; Marisa Roberto; Kevin Wickman; Paul A Slesinger; Candice Contet
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

5.  A better prognosis for genetic association studies in mice.

Authors:  Ming Zheng; David Dill; Gary Peltz
Journal:  Trends Genet       Date:  2011-11-24       Impact factor: 11.639

6.  Opiate-induced changes in brain adenosine levels and narcotic drug responses.

Authors:  M Wu; P Sahbaie; M Zheng; R Lobato; D Boison; J D Clark; G Peltz
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

7.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

8.  Mapping a barbiturate withdrawal locus to a 0.44 Mb interval and analysis of a novel null mutant identify a role for Kcnj9 (GIRK3) in withdrawal from pentobarbital, zolpidem, and ethanol.

Authors:  Laura B Kozell; Nicole A R Walter; Lauren C Milner; Kevin Wickman; Kari J Buck
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

9.  Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains.

Authors:  Corinne Berthonneche; Bastian Peter; Fanny Schüpfer; Pamela Hayoz; Zoltán Kutalik; Hugues Abriel; Thierry Pedrazzini; Jacques S Beckmann; Sven Bergmann; Fabienne Maurer
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

10.  Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery.

Authors:  Daisuke Nishizawa; Makoto Nagashima; Ryoji Katoh; Yasuo Satoh; Megumi Tagami; Shinya Kasai; Yasukazu Ogai; Wenhua Han; Junko Hasegawa; Naohito Shimoyama; Ichiro Sora; Masakazu Hayashida; Kazutaka Ikeda
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.